IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Nanjing Immunophage Biotech Co., Ltd, now recruiting.
Overview
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07508761 by Nanjing Immunophage Biotech Co., Ltd, with 52 participants planned, started 2026-06-16 and due to reach its primary completion in 2028-12-30. Interventions recorded: IPG7236 and Toripalimab Injection.
Similar pages
not linked directly; found by shared links- TrialPhase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Shares Nanjing Immunophage Biotech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.